Controversial association between polycystic ovary syndrome and breast cancer

Carvalho, Maria da Graça; Subtil, Simone; Rodrigues, Ângela; Oliveira, Joana; Figueiredo-Dias, Margarida

doi:10.1016/j.ejogrb.2019.10.011

Cited by 24 publications

(18 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 The control participants were advised to follow standard care, which included a clinic visit 7e10 days and 6 weeks postpartum. 1 The primary outcome variable was the number of hypertension-related hospital readmissions over the 6-week postpartum period. Our secondary outcome variables included hypertension-related postpartum emergency room (ER) or triage visits, the number of BPs acquired within 10 days of delivery, and the use of antihypertensives in the 6week postpartum period.…”

Section: Methodsmentioning

confidence: 99%

“…Hypertensive disorders of pregnancy (HDP) affect 10% of the pregnancies in the United States and are the most common diagnoses associated with postpartum hospital readmissions. 1,2 According to the American College of Obstetricians and Gynecologists, a blood pressure (BP) follow-up should be completed 7e10 days postpartum for women with HDP, but 50%e70% of the women do not complete the follow-up. 1,3 The objective of this study was to evaluate whether postpartum home telehealth with remote BP monitoring could reduce the readmission rates during the first 6 weeks postpartum in women with HDP, when compared with standard outpatient care.…”

Section: Objectivementioning

confidence: 99%

“…effect on breast cancer, which is the most common female cancer, androgen excess has been postulated to play a part in carcinogenesis, especially in estrogen receptor (ER)epositive breast cancer. 1 Nevertheless, previous epidemiologic studies and meta-analyses failed to provide consistent and conclusive results. Recently, Mendelian randomization (MR) has been evolving rapidly as an efficient methodological tool to make causal inference between genetically predicted risk factors and diseases.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Polycystic ovary syndrome is causally associated with estrogen receptor–positive instead of estrogen receptor–negative breast cancer: a Mendelian randomization study

Zhang

et al. 2020

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Objectivementioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Polycystic ovary syndrome is causally associated with estrogen receptor–positive instead of estrogen receptor–negative breast cancer: a Mendelian randomization study

Zhang

et al. 2020

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

“…The wide range of PCOS prevalence (3–20%) has been attributed to geographical location, race, ethnicity, or diagnose criteria applied ( 74 ). Even symptom frequency such as hirsutism, acne, insulin resistance, and obesity varies with ethnicity ( 4 ).…”

Section: Oncology and Pcosmentioning

confidence: 99%

Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis

et al. 2020

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. Epidemiological findings revealed that women with PCOS are prone to develop certain cancer types due to their shared metabolic and endocrine abnormalities. However, the mechanism that relates PCOS and oncogenesis has not been addressed. Herein, in this review article the genomic status, transcriptional and protein profiles of 264 strongly PCOS related genes (PRG) were evaluated in endometrial cancer (EC), ovarian cancer (OV) and breast cancer (BC) exploring oncogenic databases. The genomic alterations of PRG were significantly higher when compared with a set of non-diseases genes in all cancer types. PTEN had the highest number of mutations in EC, TP53, in OC, and FSHR, in BC. Based on clinical data, women older than 50 years and Black or African American females carried the highest ratio of genomic alterations among all cancer types. The most altered signaling pathways were p53 in EC and OC, while Fc epsilon RI in BC. After evaluating PRG in normal and cancer tissue, downregulation of the differentially expressed genes was a common feature. Less than 30 proteins were up and downregulated in all cancer contexts. We identified 36 highly altered genes, among them 10 were shared between the three cancer types analyzed, which are involved in the cell proliferation regulation, response to hormone and to endogenous stimulus. Despite limited PCOS pharmacogenomics studies, 10 SNPs are reported to be associated with drug response. All were missense mutations, except for rs8111699, an intronic variant characterized as a regulatory element and presumably binding site for transcription factors. In conclusion, in silico analysis revealed key genes that might participate in PCOS and oncogenesis, which could aid in early cancer diagnosis. Pharmacogenomics efforts have implicated SNPs in drug response, yet still remain to be found.

show abstract

“…The studies have shown that androgens exert inhibitory effects on mammary epithelial proliferation and breast growth. However, these effects can also inhibit progesterone and might result in the development of BBD [55]. Compelling evidence also shows that the effect of androgens on the formation of BBD and the increased risk of breast cancer is achieved mainly via conversion to estrogens [56].…”

Section: Introductionmentioning

confidence: 99%

Polycystic Ovary Syndrome and Fibrocystic Breast Disease: An Updated Review

Kunicki

Smolarczyk

2021

Horm Metab Res

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women of reproductive age. There is no clear association between PCOS and benign breast disease (BBD). The latter is a frequent benign disorder, affecting women between 20 and 50 years of age. To date, the classification remains controversial, and the risk of developing breast cancer that is associated with these changes is different depending on the histopathological findings. The most frequent changes are breast cysts, which are noted in up to 50% of patients older than 30 years of age. This up-to-date review presents the relationship between PCOS and BBD. In conclusion, there is no clear association between benign breast disease and PCOS. Further studies on a large population with prospectively collected data using updated PCOS criteria are necessary.

show abstract

Controversial association between polycystic ovary syndrome and breast cancer

Cited by 24 publications

References 77 publications

Polycystic ovary syndrome is causally associated with estrogen receptor–positive instead of estrogen receptor–negative breast cancer: a Mendelian randomization study

Polycystic ovary syndrome is causally associated with estrogen receptor–positive instead of estrogen receptor–negative breast cancer: a Mendelian randomization study

Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis

Polycystic Ovary Syndrome and Fibrocystic Breast Disease: An Updated Review

Contact Info

Product

Resources

About